Dr Paul Conway believes in a holistic, patient-centred approach to cancer care. He endeavours to empower his patients and their loved ones with current, evidence-based information in a clear and honest manner. His personalised treatment plans and strong attention to detail reassures patients that they are in the best hands.
Dr Paul Conway is a radiation oncologist at Icon Cancer Centre Richmond, Freemasons, Moreland, Mulgrave, Holmesglen and Mildura as an associate of Dr Pat Bowden. He completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) with First Class Honours at the University of Queensland in 2013. Dr Conway subsequently undertook specialist radiation oncology training at the Royal Brisbane and Women’s Hospital, Alfred Health and Peter MacCallum Cancer Centre, where he developed a strong interest in utilising advanced radiation therapy technologies to deliver high precision treatments. In 2018 he travelled to the National Cancer Centre Hospital East and Tsukuba Proton Beam Therapy Centre in Japan to further his knowledge and understanding of proton beam therapy. Dr Conway became a fellow of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 2021.
He maintains a strong interest in research and clinical trials, particularly in stereotactic radiation therapy for oligometastatic disease. As an active member of the Trans Tasman Radiation Oncology Group (TROG) and Australia and New Zealand UpToDate User Group, Dr Conway is abreast with current evidence-based practice and recruits to several open clinical trials across different cancer types. He has received several academic and research awards, and held appointments as an associate lecturer and examiner at the University of Queensland Faculty of Medicine.
Dr Conway’s personable approach allows him to establish a strong rapport with patients and their loved ones as well as develop excellent working relationships with his medical and surgical colleagues. His clinical experience covers a broad range of solid tumour malignancies with a special interest in urological cancers (including prostate cancer), gastrointestinal cancer, breast cancer, central nervous system (CNS) cancer and oligometastatic disease.